The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
The European Society of Cardiology (ESC) has announced five winners of the competitive research programme ‘Grants for Medical Research Innovation’, exclusively supported by an independent grant from Boehringer Ingelheim. The grants are awarded to research projects that will address areas of unmet medical need in thromboembolic disease.
“We were astounded at the quantity and quality of the proposals submitted. The judges had an extremely difficult task, even selecting five winners instead of four as originally planned”, said Professor Francesco Cosentino, from Karolinska, Stockholm, the chairperson of the programme’s Scientific Committee. “With one in four people dying as a result of thromboembolic disease, innovative research in this field is urgently needed. We look forward to supporting the winners to advance knowledge in this important area.”
The five winners were selected from 554 entry submissions by leading researchers and institutes worldwide and will provide important insights into cardiovascular care.
The grant winners and awardees are:
- David-Alexandre Trégouët, PhD, from the Pierre & Marie Curie Medical School, Paris, France
- Timo Heidt, MD, from Heart Center Freiburg University, Freiburg, Germany
- José Manuel Soria Fernandez, PhD, from Institute of Biomedical Research - Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain
- Christina Christersson, MD, PhD, from Uppsala University, Uppsala, Sweden
- Michael Joner, MD, from CVPath Institute in Gaithersburg, Maryland, USA, and Deutsches Herzzentrum München, Munich, Germany
According to ESC President, Professor Fausto Pinto, "The ESC has a major commitment to support cardiovascular research. These grants supported by Boehringer Ingelheim are an excellent example of transparent partnership between industry and the scientific world. Supporting this research is helping peoples’ lives."
“As a company firmly grounded in research, we believe that it is very important to support scientific initiatives. Therefore we are grateful to be able to support the ESC and the grant recipients and look forward to seeing the outcomes in the near future. We trust that the results of the grant programme will drive innovation in cardiovascular science.” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim.
The ESC Grants for Medical Research Innovation website, which includes information about the programme and selected projects, is accessible via: www.escardio.org/innovationgrants . Results of the projects are expected to be presented at the 2017 ESC Congress.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the link below for ‘Notes to Editors and References’:
Boehringer Ingelheim GmbH
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
To interview winners:
European Society of Cardiology
ESC Press Office
Phone: +33 4 92 94 86 27
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-MADISON-REALTY17.11.2017 17:22 | pressemeddelelse
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn
NCARDIA17.11.2017 13:33 | pressemeddelelse
Ncardia Announces Completion of €10.5M Investment Round
VOCALINK17.11.2017 10:37 | pressemeddelelse
Double Win for Vocalink at the 2017 Payments Awards
ENVION-AG17.11.2017 10:02 | pressemeddelelse
Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy
CHUGAI-PHARMACEUTICAL17.11.2017 00:32 | pressemeddelelse
Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors
PACIFIC-DRILLING-S.A.16.11.2017 23:10 | pressemeddelelse
Pacific Drilling Receives Approval of First Day Motions
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum